PDC Therapeutics announced that RS-0139, the lead oncology asset powered by the proprietary Sagitta^® platform technology, has successfully completed its Phase 1 clinical trial in patients with recurrent, locally advanced or metastatic solid tumors. RS-0139 uses Sagitta^® to deliver docetaxel more selectively to tumor tissue, with the aim of improving therapeutic index and addressing the long-standing efficacy-toxicity trade-off in oncology.

The completed multicenter, open-label Phase 1a/1b study evaluated dose optimization, pharmacokinetics, safety and tolerability, generating early clinical evidence that supports both RS-0139’s continued development and the broader translational potential of Sagitta^®. The platform is designed to turn known drugs, payloads and radiotherapeutics into actively targeted, scalable, controlled-release novel nanomedicines for solid tumors.

With this milestone, PDC Therapeutics is accelerating discussions with potential co-development partners exploring how Sagitta^® could help address delivery, tolerability and manufacturability challenges in their pipelines. The company is also engaging with international investors as it prepares for the next stage of growth, advancing a clinically validated targeted therapy platform with no compromise.